2610204K14Rik Inhibitors
Chemical inhibitors of the protein encoded by the gene 2610204K14Rik can be utilized to understand the functional role of this protein in cellular signaling pathways. Wortmannin and LY294002 are both inhibitors of the phosphoinositide 3-kinases (PI3K), which are upstream of the AKT signaling pathway. When these compounds are applied to cells, they can prevent the activation of AKT by inhibiting its phosphorylation. This blockade can reduce the downstream signaling events, including those that may involve the protein in question. The specificity of LY294002 is particularly useful in distinguishing the PI3K-dependent functions of the protein from other signaling events. Rapamycin, on the other hand, targets the mechanistic target of rapamycin (mTOR), a kinase involved in protein synthesis and autophagy. By inhibiting mTOR, rapamycin can impair the mTORC1 signaling pathway, which can impact the functions of various downstream proteins, potentially including the protein encoded by 2610204K14Rik if it is involved in these pathways.
Continuing with the theme of kinase inhibition, PD98059 and U0126 both target the MAPK/ERK pathway by inhibiting MEK, which is responsible for activating ERK kinases. By preventing the phosphorylation of ERK, these inhibitors can decrease the activity of proteins that are regulated by the MAPK/ERK pathway, which includes a myriad of cellular responses such as cell proliferation and differentiation. Additionally, SP600125 inhibits the c-Jun N-terminal kinase (JNK), and SB203580 selectively inhibits p38 MAP kinase, both of which are critical in stress and inflammatory response signaling. The protein encoded by 2610204K14Rik, if it acts downstream of JNK or p38 MAP kinase, can be functionally inhibited by these compounds, leading to an interruption of its role in these pathways. Lastly, PP2 inhibits Src family tyrosine kinases, which are involved in various cellular processes like cell adhesion and survival, and its inhibition can suppress the activity of downstream proteins, including the one of interest, assuming it is part of the Src kinase signaling network. These inhibitors collectively provide a suite of tools for probing the function of the protein encoded by 2610204K14Rik within complex cellular signaling networks.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a synthetic molecule that functions as a specific inhibitor of PI3Ks. Similar to Wortmannin, LY294002's inhibition of PI3K can lead to decreased AKT activation. By preventing the phosphorylation and activation of AKT, LY294002 can disrupt downstream signaling that may regulate the activity of 2610204K14Rik, provided 2610204K14Rik is a downstream target in the PI3K/AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a macrolide compound that inhibits the mechanistic target of rapamycin (mTOR), a key kinase in cellular growth and metabolism. By inhibiting mTOR, rapamycin can block the mTORC1 signaling pathway, which is involved in protein synthesis and autophagy. This inhibition can downregulate the functions that are potentially regulated by 2610204K14Rik, assuming 2610204K14Rik is involved in processes that are downstream of mTORC1 signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a synthetic compound that selectively inhibits MEK, which in turn blocks the phosphorylation and activation of ERK kinases. Since ERK is involved in the MAPK/ERK signaling pathway, PD98059's inhibition of this pathway can lead to a decrease in the phosphorylation state of many proteins regulated by ERK, potentially including 2610204K14Rik, assuming that 2610204K14Rik is regulated by the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 can suppress the JNK signaling pathway, which is implicated in a variety of cellular processes, including cell proliferation, differentiation, and apoptosis. If 2610204K14Rik is regulated by the JNK pathway, then inhibition by SP600125 can lead to functional inhibition of 2610204K14Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole derivative that acts as a selective inhibitor of p38 MAP kinase. Inhibiting p38 MAP kinase can disrupt the p38 MAPK signaling pathway, which is involved in inflammatory responses and stress. If 2610204K14Rik is a protein whose activity is modulated by the p38 MAPK pathway, then inhibition by SB203580 could result in functional inhibition of 2610204K14Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src kinase activity, PP2 can affect signaling pathways that are mediated by Src kinases, including cell adhesion, migration, proliferation, and survival. Assuming that 2610204K14Rik is a protein that acts downstream of Src kinase signaling, PP2's inhibition of Src kinases can lead to the functional inhibition of 2610204K14Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a non-competitive inhibitor of MEK1/2, which prevents the activation of ERK1/2. By inhibiting MEK1/2 and therefore the activation of ERK1/2, U0126 can suppress the MAPK/ERK signaling pathway. Assuming that 2610204K14Rik is regulated by the MAPK/ERK pathway, U0126 would functionally inhibit 2610204K14Rik by preventing its phosphorylation and activation through this pathway. | ||||||